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The 2003 San Antonio Breast Cancer Symposium was a vindication of sorts for an embattled biotechnology company and its controversial founder. The Santa Monica, Calif.-based American Pharmaceutical Partners (APP) presented highly anticipated phase III data for ABI-007, a new paclitaxel formulation, in metastatic breast cancer. Going head-to-head against the standard paclitaxel formulation Taxol, ABI-007 (trade name Abraxane) roughly doubled patient response rates and achieved longer tumor time-to-progression at no cost in toxicity. Company founder and chief executive officer Patrick SoonShiong, M.D., expects to apply for U.S. Food and Drug Administration approval for ABI-007 early in 2004.
APP's drug reformulation ambitions go beyond paclitaxel. At the symposium, the company also unveiled a provocative theory to explain why its albumin nanoparticle-based formulation performed so much better than Taxol. The theory, involving a novel transport mechanism that preferentially targets tumors, could have broad implications for delivery of other cancer drugs. APP's theory "is really going to fire the imagination, I think, of the oncology community," said trial investigator Joyce O'Shaughnessy, M.D., of the Baylor-Charles A. Sammons Cancer Center in Dallas.
The successful results were badly needed by APP. The company has seen its stock roller-coaster in the last few months, and shareholders have filed seven different lawsuits accusing APP of over-hyping its results. The business press has been critical, with Barron's raising questions about the clinical trials and Forbes detailing the history of Soon-Shiong's failed foray into diabetes therapy in the early 1990s, an episode that led to bitter and expensive legal battles with his brother. These results also impressed several breast cancer experts with no connection to the trial or the company. "I certainly hope that regulatory agents … make a decision regarding the possibility of this drug being approved, so that it is available for patient use," Edith Perez, M.D., director of the breast cancer program at the Mayo Clinic, said at the meeting.
Making a Better Taxol
ABI-007 has been long in development. Soon-Shiong and chemist Neil Desai, Ph.D., conceived the drug after attending a 1992 National Cancer Institute-organized meeting on Taxol, which had just received marketing approval. Taxol was amazingly effective, but the meeting revealed some serious problems, mainly with toxicity. That is because the drug is formulated with the castor oil derivative Cremophor to make it water soluble. "It was clear to the scientists of the world that Cremophor was not a safe material," said SoonShiong. Cremaphor often leads to hypersensitivity reactions in patients, who must be pretreated with steroids.
Soon-Shiong and Desai created a Cremophor-free paclitaxel formulation by fusing the compound with albumin, a natural protein used by the body to transport water-insoluble compounds. The resulting drug, ABI-007, is a suspension of albumin nanoparticles, each of which contains a tiny bit of active drug. No steroid pretreatment is needed. Clinical trials, begun in 1998, were promising, but the head-to-head trial with Taxol has now clinched ABI-007's clinical superiority. "There's no question in my mind that this drug will eventually make it for use," To begin with, he said, the Cremophor in Taxol not only leads to toxicity, but keeps paclitaxel from reaching the tumor. That's because Cremophor paclitaxel becomes entrapped in micelles, tiny hydrophobic droplets in plasma. This entrapment phenomenon, said Soon-Shiong, explains earlier studies showing no effect on tumors from increasing Taxol dose. "By trapping the drug in plasma and increasing the dose, you really have no opportunity to achieve a dose response," he said. ABI-007 avoids that pitfall and frees paclitaxel to pass from the vascular system into tumors. "When you were giving a higher dose of Taxol, you were giving a higher dose of Cremophor," said Soon-Shiong. "We've been able now to drive the drug into the tumor and maximize the potential of this tubulin poison."
Keeping the drug in contact with the tumor is another problem with current chemotherapy. High intratumoral pressure, a phenomenon first described by Rakesh Jain, M.D., of Harvard Medical School in 1996, tends to push conventional drugs out of the tumor interstitial space. "A drug in solution gets kicked right out," said Soon-Shiong. "If it's in a nanoparticle, it gets in via the leaky tumor vasculature and gets entrapped."
In San Antonio, APP presented data showing a 33% greater tumor penetration into mouse xenografts by ABI-007 compared with Taxol. Based on a series of preclinical tests by APP (and recent cell biology work by others), SoonShiong believes that the drug reaches the tumor by a novel mechanism. Some ABI-007 penetrates the tumor via leaky junctions in tumor vasculature and stays there because of the tumor's impaired lymphatic system. More of the drug engages albumin receptors-gp60 receptors-inside the tumor blood vessel. The receptors, in turn, fold into sacs called caveolae that then empty the drug into the tumor interstitial space, where the freed paclitaxel subsequently penetrates tumor cells and kills them via microtubule binding. "The molecules are literally pulled through" the blood vessel walls via the albumin receptors, Soon-Shiong explained. Thus ABI-007 is able to take advantage of albumin's normal molecular machinery, which facilitates macromolecule transport to cells-especially tumor cells, which presumably have evolved to maximize nutrient delivery.
New Hope for High Dose?
This explanation for ABI-007's clinical potency is still theoretical. "The exact relevance to the clinical situation we don't know," cautioned O'Shaughnessy. But if formulating paclitaxel with albumin can help it get to tumors, the same strategy should work for other chemotherapy drugs. This might get around one of the biggest obstacles in chemotherapy for solid tumors: the failure of high doses to achieve better kill rates. "What's important is not how much drug you give the patient, but how much drug gets to the tumor," said Craig Henderson, M.D., of the University of California at San Francisco. "So [ABI-007] then becomes a tool for us to begin to get proof of principle of this concept, that it's the dose of drug that's at the tumor that's the important endpoint."
Soon-Shiong said his company plans to formulate other water-insoluble chemotherapy drugs, possibly including docetaxel and the camptothecins, with albumin nanoparticles. Other cytotoxic molecules, shelved because of delivery problems, are also candidates. "These molecules are active, we want to get them to the tumor," Soon-Shiong said. "We have a potential way. It may be as simple as that."
Whether Soon-Shiong's "Nanoparticle Albumin Bound" (NAB) technology becomes a general platform for anticancer agents-and other waterinsoluble drugs-remains to be seen. But the maverick ex-transplant surgeon appears to have won over the medical community to ABI-007. "I'm damn glad he was able to get this agent available for patients," said Von Hoff. "Because, I will tell you, without question, that this has helped a lot of people already."
-Ken Garber 
